Nexiguran ziclumeran · MAGNITUDE-2
The FDA lifted the MAGNITUDE-2 hold in January 2026 for ATTRv polyneuropathy. Do not substitute the separate MAGNITUDE cardiomyopathy study or infer that its hold changed identically. nexiguran ziclumeran — phase 3 study in Neuromuscular Disease, Neuromuscular Diseases (NMD), Neurodegenerative Disease. NCT06672237 lists Modified Neuropathy Impairment Score +7 (mNIS+7) as a primary outcome (18 Months). Registry status: recruiting.
What matters
Track what the company has actually announced, the study or asset involved, and the evidence needed to confirm the milestone.
- Specify the exact future analysis/cohort and verify that it remains unpublished before creating any tradeable question.
- Registry design and recruitment status are not evidence of efficacy or regulatory approval.
- Primary completion is not a guaranteed topline publication or regulatory decision date.
- Registry primary completion: 2027-07 (estimated); verify independently before using it as a catalyst date.
- An active study record does not establish that its primary outcome is still unannounced. Review sponsor disclosures before promotion to a future catalyst.
- The registry lists 2 primary outcome measures. A market must explicitly specify which endpoint or conjunction resolves YES; this card highlights one measure only.
Primary evidence
Phase 3 monitor — result date unconfirmed
Potential outcome market
Will nexiguran ziclumeran meet the prespecified primary endpoint in NCT06672237 by a listing deadline still to be specified?
This event is research, not a listed market. A market needs a precise question, resolution rules and liquidity before trading opens.